European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Posted on: 26/04/2018 - 13:27

Vaccines matter for each of us: yearly, they prevent 2.7 million people from contracting measles, one million from getting whooping cough and two million babies from getting tetanus. They eradicated smallpox. They stopped polio, a dreadful disease affecting millions of children, in almost all... more

Field of Interest: European Union Medical News
Type: News Feed

Human medicines European public assessment report (EPAR): Lunsumio, mosunetuzumab, Date of authorisation: 03/06/2022, Revision: 8, Status: Authorised

Submitted by Anonymous (not verified) on 2 July 2026 - 12:00

Human medicines European public assessment report (EPAR): Lunsumio, mosunetuzumab, Date of authorisation: 03/06/2022, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Alkindi, hydrocortisone, Date of authorisation: 09/02/2018, Revision: 13, Status: Authorised

Submitted by Anonymous (not verified) on 2 July 2026 - 11:42

Human medicines European public assessment report (EPAR): Alkindi, hydrocortisone, Date of authorisation: 09/02/2018, Revision: 13, Status: Authorised

Opinion/decision on a Paediatric investigation plan (PIP): Fintepla, fenfluramine hydrochloride, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Neurology, PIP number: P/0390/2022

Submitted by Anonymous (not verified) on 2 July 2026 - 10:00

Opinion/decision on a Paediatric investigation plan (PIP): Fintepla, fenfluramine hydrochloride, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Neurology, PIP number: P/0390/2022

Opinion/decision on a Paediatric investigation plan (PIP): Ultomiris, ravulizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Blood and lymphatic system disorders, PIP number: P/0128/2023

Submitted by Anonymous (not verified) on 2 July 2026 - 9:45

Opinion/decision on a Paediatric investigation plan (PIP): Ultomiris, ravulizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Blood and lymphatic system disorders, PIP number: P/0128/2023

Human medicines European public assessment report (EPAR): Elaprase, idursulfase, Date of authorisation: 08/01/2007, Revision: 27, Status: Authorised

Submitted by Anonymous (not verified) on 2 July 2026 - 8:19

Human medicines European public assessment report (EPAR): Elaprase, idursulfase, Date of authorisation: 08/01/2007, Revision: 27, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More